Literature DB >> 16304968

[Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].

José Terán Dávila1, Alejandro D Teppa Garrán.   

Abstract

The selective strogen receptors modulators (SERMs) were initially developed as antistrogens for the treatment of breast cancer, but their unusual properties have led to their use in the treatment and prevention of other diseases as well. SERMs bind the strogen receptor (ER) and modulated ER-mediated gene transcription. Tamoxifen is an effective treatment for hormone responsive breast cancer and can prevent breast cancer in high-risk women. Raloxifene was approved for the prevention and treatment of osteoporosis in postmenopausal women, also appears to prevent breast cancer. Other SERMs are in development, with the goal of improving efficacy and reducing toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304968

Source DB:  PubMed          Journal:  Ginecol Obstet Mex        ISSN: 0300-9041


  2 in total

1.  Preliminary Pharmacogenomic-Based Predictive Models of Tamoxifen Response in Hormone-dependent Chilean Breast Cancer Patients.

Authors:  Carla Miranda; Macarena Galleguillos; Roberto Torres; Karla Tardón; Dante D Cáceres; Kuen Lee; María A Redal; Nelson M Varela; Luis A Quiñones
Journal:  Front Pharmacol       Date:  2021-11-25       Impact factor: 5.810

Review 2.  Effects of estrogen receptor modulators on cytoskeletal proteins in the central nervous system.

Authors:  Julia J Segura-Uribe; Rodolfo Pinto-Almazán; Angélica Coyoy-Salgado; Claudia E Fuentes-Venado; Christian Guerra-Araiza
Journal:  Neural Regen Res       Date:  2017-08       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.